Guideline/Drug Updates and Errata
RxPrep content (e.g., NAPLEX® Course Book, MPJE®/CPJE Manuals and QBanks) is up-to-date at the time of publishing, but drug information and laws can change at any time. If information changes after a product is published, we will post exam-relevant updates in the Guideline/Drug Updates tables below. If we find anything that needs a correction or clarification, it will be included in the Errata tables below.
Updates: 2023 UWorld RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2022-May 2023
| Page | Update Type | Description |
|---|---|---|
| Chapters 15-17: Compounding I, II, and III | ||
| p. 226-281 | Guideline Update | Revised United States Pharmacopeia (USP) chapters 795 (Nonsterile Preparations)
and 797 (Sterile Preparations) were published on November 1, 2022, and the changes will become official on
November 1, 2023. Since the changes will not be official until November 1, 2023, these updates are unlikely to
have an immediate impact on the compounding content tested on the NAPLEX. USP 795 USP 797 |
| Chapter 31: Chronic Heart Failure and Chapter 44: Diabetes | ||
| p. 466-469, 471 | Guideline Update | The American Heart Association (AHA) and American College of Cardiology (ACC)
released the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and aldosterone receptor antagonists are now considered initial medications for all patients with heart failure with reduced ejection fraction (HFrEF) without contraindications. 2022 AHA/ACC Heart Failure Guidelines |
| Chapter 42: Chronic Obstructive Pulmonary Disease | ||
| p. 590-591 | Guideline Update | The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released the
2023 guidelines for COPD diagnosis, management, and prevention. Key changes that could impact testing include:
|
| Chapter 44: Diabetes | ||
| p. 607-608 | Guideline Update | The 2023 American Diabetes Association (ADA) Standards of Care update was published. Key changes that could impact testing include: p. 607: Comprehensive Care, section on Cholesterol Control
p. 607: Comprehensive Care, section on Diabetic Kidney Disease
p. 607: Comprehensive Care, section on Blood Pressure Control
p. 608: Treatment for Type 2 Diabetes and Treatment Algorithm
|
Errata: 2023 UWorld RxPrep Course Book
Corrections or clarifications for the 2023 RxPrep Course Book
| Page | Description | |
|---|---|---|
| Chapter 27: Dyslipidemia | ||
| p. 426 | In the Statin Treatment Intensity Definitions and Selection Options table, pitavastain doses of 1-4 mg are considered moderate intensity. | |
Updates: 2024 UWorld RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2023 – May 2024
| Page | Update Type | Description | ||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chapter 15: Compounding I | ||||||||||||||||||||||||||||||||||||||||
| p. 227, 231, 237 | Guideline Update |
Revised United States Pharmacopeia (USP) chapters 795 (Non-sterile Preparations) and 797 (Sterile Preparations) became official on November 1, 2023. The updates most relevant for testing that impact this chapter include: p. 227: Non-Sterile Compounding
p. 231: Sterile Compounding for Emergencies and Segregated Compounding Area
p. 237: Compounding Staff Training
|
||||||||||||||||||||||||||||||||||||||
| Chapter 17: Compounding III | ||||||||||||||||||||||||||||||||||||||||
| p. 266, 273, 277-278 | Guideline Update |
Revised USP chapters 795 and 797 became official on November 1, 2023. Key updates that impact this chapter include: p. 273: Selecting the Beyond-Use Date for Non-Sterile Preparations
p. 277: Sterile Preparation and Risk
p. 278: Determining the Beyond-Use Date Based on CSP Risk Level
|
||||||||||||||||||||||||||||||||||||||
| Chapter 20: Immunizations | ||||||||||||||||||||||||||||||||||||||||
| p. 313, 318 | Guideline Update |
The Advisory Committee on Immunization Practices (ACIP) updated their recommendations for influenza vaccine administration in patients with an egg allergy (of any severity). The requirement to administer select vaccines (i.e., those that are not egg-free) in a medical setting under the supervision of a healthcare provider has been removed. No additional safety precautions are required, although providers should always be prepared for emergent situations with any vaccine administration. |
||||||||||||||||||||||||||||||||||||||
| p. 314, 320 | Guideline Update |
The Centers for Disease Control (CDC) released the 2024 Immunization Schedules for Children and Adolescents and Adults. The updates most relevant for testing that impact this chapter include: p. 314: New respiratory syncytial virus (RSV) vaccine and antibody recommendations for select populations
p. 320: Pneumococcal vaccines
|
||||||||||||||||||||||||||||||||||||||
| Chapter 44: Diabetes | ||||||||||||||||||||||||||||||||||||||||
| p. 600-601 | Guideline Update |
The 2024 American Diabetes Association (ADA) Standards of Care update was published. There were no significant changes that impacted the 2024 UWorld RxPrep course book content. |
||||||||||||||||||||||||||||||||||||||
| Chapter 47: Contraception & Infertility | ||||||||||||||||||||||||||||||||||||||||
| p. 652–654 | New Drug | The FDA has approved norgestrel 0.075 mg (Opill) as the first nonprescription (OTC) oral contraceptive. Opill is a progestin-only pill that should be taken once daily at the same time every day. | ||||||||||||||||||||||||||||||||||||||
Updates: 2024 UWorld RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2023 – May 2024
| Chapter 15: Compounding I | ||||||||||||||||||||||||||||||||||||||||
| Page p. 227, 231, 237 |
Update Type Guideline Update |
|||||||||||||||||||||||||||||||||||||||
|
Revised United States Pharmacopeia (USP) chapters 795 (Non-sterile Preparations) and 797 (Sterile Preparations) became official on November 1, 2023. The updates most relevant for testing that impact this chapter include: p. 227: Non-Sterile Compounding
p. 231: Sterile Compounding for Emergencies and Segregated Compounding Area
p. 237: Compounding Staff Training
|
||||||||||||||||||||||||||||||||||||||||
| Chapter 17: Compounding III | ||||||||||||||||||||||||||||||||||||||||
| Page p. 266, 273, 277-278 |
Update Type Guideline Update |
|||||||||||||||||||||||||||||||||||||||
|
Revised USP chapters 795 and 797 became official on November 1, 2023. Key updates that impact this chapter include: p. 273: Selecting the Beyond-Use Date for Non-Sterile Preparations
p. 277: Sterile Preparation and Risk
p. 278: Determining the Beyond-Use Date Based on CSP Risk Level
|
||||||||||||||||||||||||||||||||||||||||
| Chapter 20: Immunizations | ||||||||||||||||||||||||||||||||||||||||
| Page p. 313, 318 |
Update Type Guideline Update |
|||||||||||||||||||||||||||||||||||||||
|
The Advisory Committee on Immunization Practices (ACIP) updated their recommendations for influenza vaccine administration in patients with an egg allergy (of any severity). The requirement to administer select vaccines (i.e., those that are not egg-free) in a medical setting under the supervision of a healthcare provider has been removed. No additional safety precautions are required, although providers should always be prepared for emergent situations with any vaccine administration. |
||||||||||||||||||||||||||||||||||||||||
| p. 314, 320 | Guideline Update | |||||||||||||||||||||||||||||||||||||||
|
The Centers for Disease Control (CDC) released the 2024 Immunization Schedules for Children and Adolescents and Adults. The updates most relevant for testing that impact this chapter include: p. 314: New respiratory syncytial virus (RSV) vaccine and antibody recommendations for select populations
p. 320: Pneumococcal vaccines
|
||||||||||||||||||||||||||||||||||||||||
| Chapter 44: Diabetes | ||||||||||||||||||||||||||||||||||||||||
| Page p. 600-601 |
Update Type Guideline Update |
|||||||||||||||||||||||||||||||||||||||
| The 2024 American Diabetes Association (ADA) Standards of Care update was published. There were no significant changes that impacted the 2024 UWorld RxPrep course book content. | ||||||||||||||||||||||||||||||||||||||||
| Chapter 47: Contraception & Infertility | ||||||||||||||||||||||||||||||||||||||||
| Page p. 652–654 |
Update Type New Drug |
|||||||||||||||||||||||||||||||||||||||
| The FDA has approved norgestrel 0.075 mg (Opill) as the first nonprescription (OTC) oral contraceptive. Opill is a progestin-only pill that should be taken once daily at the same time every day. | ||||||||||||||||||||||||||||||||||||||||
Updates: 2023 UWorld RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2022-May 2023
| Chapters 15-17: Compounding I, II, and III |
||
| Page p. 226-281 |
Update type Guideline Update |
|
| Revised United States Pharmacopeia (USP) chapters 795 (Nonsterile Preparations) and 797 (Sterile Preparations) were published on November 1, 2022, and the changes will become official on November 1, 2023. Since the changes will not be official until November 1, 2023, these updates are unlikely to have an immediate impact on the compounding content tested on the NAPLEX. USP 795 USP 797 |
||
| Chapter 31: Chronic Heart Failure and Chapter 44: Diabetes |
||
| Page p. 466-469, 471 |
Update type Guideline Update |
|
| The American Heart Association (AHA) and American College of Cardiology (ACC) released the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and aldosterone receptor antagonists are now considered initial medications for all patients with heart failure with reduced ejection fraction (HFrEF) without contraindications. 2022 AHA/ACC Heart Failure Guidelines |
||
| Chapter 42: Chronic Obstructive Pulmonary Disease | ||
| Page p. 590-591 |
Update type Guideline Update |
|
| The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released the 2023 guidelines for COPD diagnosis, management, and prevention. Key changes that could impact testing include: The combined assessment of COPD has been changed from an ABCD system to an ABE system, where the previous groups of C and D are combined into one new group (E). Any patient with elevated risk of exacerbations is included in group E. The recommendations for initial pharmacologic therapy have been modified to match the new ABE system. Initial treatment by group includes:
|
||
| Chapter 44: Diabetes | ||
| Page p. 607-608 |
Update type Guideline Update |
|
| The 2023 American Diabetes Association (ADA) Standards of Care update was published. Key changes that could impact testing include: p. 607: Comprehensive Care, section on Cholesterol Control Goal LDL targets are now:
p. 607: Comprehensive Care, section on Diabetic Kidney Disease
|
||
Errata: 2023 UWorld RxPrep Course Book
Corrections or clarifications for the 2023 RxPrep Course Book
| Chapter 27: Dyslipidemia | ||
| Page p. 426 |
||
| In the Statin Treatment Intensity Definitions and Selection Options table, pitavastain doses of 1-4 mg are considered moderate intensity. |
MPJE Updates: 8th Edition MPJE Review Course
MPJE-relevant updates from April 2024 – present
There are currently no significant updates or errata affecting the content of the UWorld RxPrep 8th Edition MPJE Review Course: Pharmacy Law Summary.
CPJE Updates: 8th Edition California Law Summary for CPJE
CPJE-relevant updates from June 2023 – present
| Page | Update Type | Description |
|---|---|---|
| Chapter 2: Pharmacy Operations | ||
| p. 19 |
Law change Effective January 2023 |
Controlled substance inventory reports must be prepared using an exact physical count, not an estimate, for all federal controlled substance schedules (i.e., schedules II–V) that a pharmacy has in stock (both unopened and opened containers). Prior to this law change, an estimated count was permissible for opened containers of schedule III–V controlled substances based on the number of dosage units. |
| Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing | ||
| p. 49-50 | Law update |
The Notice to Consumers poster has been updated. The poster is now titled “Talk to the Expert” and must replace the “Ask Your Pharmacist!” poster. The content of the poster has been updated to caution consumers to “check” for a list of key information regarding their prescription before leaving the pharmacy. The poster continues to notify consumers of their rights as a patient at the pharmacy. The new poster also includes a QR code that links consumers to other language translations of the poster. If the poster is displayed using a video screen, the QR code must still be capable of being read and displayed for sufficient time for consumers to access the code. |
| p. 57 |
New Law Effective May 2024 |
The California Department of Public Health has issued a statewide standing order for epinephrine which authorizes a CA school, school district, or county office of education to obtain epinephrine auto-injectors for K-12 schools (ie, elementary, middle, junior high, and high schools). The standing order is acceptable at all pharmacies throughout CA to dispense epinephrine auto-injectors. The maximum number of auto-injectors is four per school per calendar year. If used, these can be refilled (which does not count toward the quantity limit). |
| Chapter 4: Pharmacy Practice Part 2: Furnishing, Administering and Clinical Services | ||
| p. 69 |
New Law Effective September 2023 |
A pharmacist can furnish oral drugs approved or authorized by the FDA for COVID-19 to a patient that has had a positive test for SARS-CoV-2. When furnishing, the pharmacist must:
|
| p. 74 |
New Drug Effective July 2023 |
The FDA has approved a new over-the-counter (OTC) naloxone product (brand name RiVive) indicated for the emergency treatment of known or suspected opioid overdose. RiVive will be available as a 3-milligram nasal spray. |
| p. 80-81 |
Law change Effective February 2024 |
The law for furnishing HIV pre-exposure prophylaxis (PrEP) has been updated as follows:
|
| Chapter 2: Pharmacy Operations | ||
| p. 19 |
Law change Effective January 2023 |
|
| Controlled substance inventory reports must be prepared using an exact physical count, not an estimate, for all federal controlled substance schedules (i.e., schedules II–V) that a pharmacy has in stock (both unopened and opened containers). Prior to this law change, an estimated count was permissible for opened containers of schedule III–V controlled substances based on the number of dosage units. | ||
| Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing | ||
| p. 49-50 | Law update | |
|
The Notice to Consumers poster has been updated. The poster is now titled “Talk to the Expert” and must replace the “Ask Your Pharmacist!” poster. The content of the poster has been updated to caution consumers to “check” for a list of key information regarding their prescription before leaving the pharmacy. The poster continues to notify consumers of their rights as a patient at the pharmacy. The new poster also includes a QR code that links consumers to other language translations of the poster. If the poster is displayed using a video screen, the QR code must still be capable of being read and displayed for sufficient time for consumers to access the code. |
||
|
Chapter 4: Pharmacy Practice
Part 2: Furnishing, Administering and Clinical Services |
||
|
Page
p. 69 |
New Law
Effective September 2023 |
|
A pharmacist can furnish oral drugs approved or authorized by the FDA for COVID-19 to a patient that has had a positive test for SARS-CoV-2. When furnishing, the pharmacist must:
|
||
|
Page
p. 74 |
New Drug
Effective July 2023 |
|
| The FDA has approved a new over-the-counter (OTC) naloxone product (brand name RiVive) indicated for the emergency treatment of known or suspected opioid overdose. RiVive will be available as a 3-milligram nasal spray. | ||
|
Page
p. 80-81 |
Law change
Effective February 2024 |
|
|
The law for furnishing HIV pre-exposure prophylaxis (PrEP) has been updated as follows:
|
||
CPJE Errata: 8th Edition California Law Summary for CPJE
Corrections or clarifications for the 8th Edition UWorld RxPrep CPJE manual
| Page | Description | |
|---|---|---|
| Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing | ||
| p. 32 |
In the Optometrist (OD) row of the table, the right column should read: Must be certified by the Board of Optometry to prescribe drugs. These optometrists will have three letters starting with a T at the end of their license number. Independent authority:
Dependent authority:
|
|
| Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | ||
| p. 135 |
The first sentence of the second paragraph below the “Purchase Requirements for OTC Sales” section should read: Although the DEA requires that the logbook be kept in a secure location for at least two years, California law is more strict and requires records to be kept for at least three years. |
|
| Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing | ||
| Page p. 32 |
||
|
In the Optometrist (OD) row of the table, the right column should read: Must be certified by the Board of Optometry to prescribe drugs. These optometrists will have three letters starting with a T at the end of their license number. Independent authority:
Dependent authority:
|
||
| Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | ||
| p. 135 |
The first sentence of the second paragraph below the “Purchase Requirements for OTC Sales” section should read: Although the DEA requires that the logbook be kept in a secure location for at least two years, California law is more strict and requires records to be kept for at least three years. |
|